Trial Profile
A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms PARAMOUNT
- Sponsors Eli Lilly and Company
- 10 Sep 2019 Results of exploratory analysis by using data from four studies (KEYNOTE-189, PARAMOUNT, PRONOUNCE, and JVBL) presented at the 20th World Conference on Lung Cancer.
- 21 Jul 2019 This trial has been completed in United kingdom as reported by European Clinical Trials Database.
- 18 Oct 2017 Results of descriptive safety analysis from three randomised trials (PRONOUNCE, PARAMOUNT and KEYNOTE-021 Cohort G) presented at the 18th World Conference on Lung Cancer.